# Effects of branched-chain amino acids on iron deficiency-induced muscle atrophy

**Authors:** Miki Kawanaka, Mingyuan Wang, Toru Iwahashi, Mai Konishi, Katsuyuki Konishi, Seira Sato, Hiroyuki Tanaka, Ken Nakata

PMC · DOI: 10.1016/j.bbrep.2026.102451 · 2026-01-17

## TL;DR

Iron deficiency causes muscle atrophy, and BCAA only partially helps by affecting some muscle breakdown genes but not overall muscle size.

## Contribution

This study reveals BCAA's limited effectiveness in preventing muscle atrophy caused by iron deficiency.

## Key findings

- Iron deficiency reduces myotube diameter and activates atrogenes like Atrogin-1 and MuRF-1.
- BCAA partially suppresses Atrogin-1 but does not prevent muscle atrophy or affect MuRF-1.
- BCAA has limited efficacy in counteracting iron deficiency-induced muscle atrophy.

## Abstract

Iron deficiency (ID) is a potential contributor to skeletal muscle atrophy through disruption of the balance between protein synthesis and degradation. This muscle loss is associated with sarcopenia and locomotive syndrome, conditions that impair mobility and reduce healthy life expectancy. While branched-chain amino acids (BCAA) are known to attenuate dexamethasone-induced muscle atrophy, its effectiveness against ID-induced atrophy has not been fully elucidated. This study aims to investigate the effects of BCAA on ID-induced muscle atrophy in C2C12 myotubes treated with the iron chelator deferoxamine (DFO). Results showed that DFO significantly reduced myotube diameter and upregulated atrogenes such as Atrogin-1 and MuRF-1, accompanied by increased p-AMPK and p-eEF2, and decreased p-Akt levels. BCAA supplementation partially suppressed Atrogin-1 expression but had no effect on MuRF-1 or myotube diameter. Additionally, p-p70S6K was significantly upregulated in the BCAA + DFO group, while p-eEF2 levels remained elevated, similar to the DFO group. These findings suggest that ID may activate alternative catabolic signaling, such as the NF-kB pathway, thereby counteracting the anabolic effects of BCAA via the Akt signaling pathway. Thus, BCAA has limited efficacy in preventing muscle atrophy under iron-deficient conditions. In conclusion, BCAA may partially promote muscle protein synthesis-related signaling pathways, but is insufficient to prevent muscle atrophy induced by ID.

•Iron deficiency leads to reduced myotube diameter and upregulation of atrogenes.•BCAA suppressed Atrogin-1 expression but had no effect on MuRF-1 or myotube diameter.•BCAA has limited efficacy in preventing muscle atrophy under iron-deficient conditions.

Iron deficiency leads to reduced myotube diameter and upregulation of atrogenes.

BCAA suppressed Atrogin-1 expression but had no effect on MuRF-1 or myotube diameter.

BCAA has limited efficacy in preventing muscle atrophy under iron-deficient conditions.

## Linked entities

- **Genes:** Fbxo32 (F-box protein 32) [NCBI Gene 67731], TRIM63 (tripartite motif containing 63) [NCBI Gene 84676]
- **Proteins:** Akt (Akt kinase)
- **Chemicals:** deoxyribonucleic acid (PubChem CID 44135672), deferoxamine (PubChem CID 2973), branched-chain amino acids (PubChem CID 9886134)

## Full-text entities

- **Genes:** PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) [NCBI Gene 5562] {aka AMPK, AMPK alpha 1, AMPKa1}, FBXO32 (F-box protein 32) [NCBI Gene 114907] {aka Fbx32, MAFbx}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, EEF2 (eukaryotic translation elongation factor 2) [NCBI Gene 1938] {aka EEF-2, EF-2, EF2, SCA26}, TRIM63 (tripartite motif containing 63) [NCBI Gene 84676] {aka CMH31, IRF, MURF1, MURF2, RNF28, SMRZ}, RPS6KB1 (ribosomal protein S6 kinase B1) [NCBI Gene 6198] {aka PS6K, S6K, S6K-beta-1, S6K1, STK14A, p70 S6KA}
- **Diseases:** muscle atrophy (MESH:D009133), muscle loss (MESH:D009135), atrophy (MESH:D001284), sarcopenia (MESH:D055948), ID (MESH:D000090463), locomotive syndrome (MESH:D020233)
- **Chemicals:** iron (MESH:D007501), dexamethasone (MESH:D003907), BCAA (MESH:D000597), DFO (MESH:D003676)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12854053/full.md

---
Source: https://tomesphere.com/paper/PMC12854053